> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 6.1% Of Arcutis Without Seeking To Influence Control
- URL: https://www.bullished.co/state-street-holds-6-1-of-arcutis-without-seeking-to-influence-control-41c6c7c8/
- Published: 2026-11-10T11:46:21.000Z
- Updated: 2026-11-10T11:46:21.000Z
- Description: Arcutis raised its 2026 revenue outlook while commercial spending climbed faster than product sales.
- Author: Matteo Parrino
- Tags: SEC Filings, ARQT, Industry: Healthcare

State Street reported a [6.1% passive stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000615/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Arcutis Biotherapeutics](https://www.bullished.co/tag/arqt/), which develops and sells skin-disease treatments, in an SEC ownership filing Tuesday. The holding totaled 7,718,628 common shares as of September 30, 2026, rather than representing a purchase made on the filing date.

## A Holding Without A Control Bid

State Street certified that its Arcutis shares were bought and held as part of its regular business, without an aim or effect of influencing the company's control. The passive ownership disclosure describes the holding's purpose, not a campaign to change management.

State Street had [shared voting authority](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000615/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 7,399,852 shares and sole voting authority over none. Its shared authority to dispose of shares covered the full 7,718,628-share holding.

Arcutis had a market capitalization of $3.3 billion as of 6:41 a.m. ET Tuesday.

## Sales Grow, Spending Grows Faster

Arcutis reported third-quarter net product revenue of [$143.9 million](https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-inc-arqt-q3-230839811.html?ref=bullished.co), up 45% from a year earlier, and raised its 2026 net revenue forecast to $535 million–$545 million. Selling and administrative expenses rose faster: up 60% to $99.6 million, which the company attributed largely to more media spending and an expanded sales force.

The commercial push centers on ZORYVE, a steroid-free medicine applied once daily. Its roflumilast-based creams and foam are approved in the United States for plaque psoriasis, atopic dermatitis and seborrheic dermatitis, and the medicine is also sold in Canada. Arcutis markets it to dermatologists and is extending its reach to primary care providers and pediatricians.

Arcutis generated [$18.9 million](https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-inc-arqt-q3-230839811.html?ref=bullished.co) in positive operating cash flow, but said expenses would remain elevated in the fourth quarter and into 2027\. The company said the commercial payoff from its primary-care and pediatric sales force and virtual health platform remained uncertain until 2027.

Arcutis Chief Financial Officer Lata Bhairavan said the company would wait until the year closes before providing 2027 guidance.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: ARCUTIS BIOTHERAPEUTICS INC (ARQT)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000615/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...](https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-inc-arqt-q3-230839811.html?ref=bullished.co) — Yahoo Finance
- [Arcutis Biotherapeutics Reports Inducement Grants Under](https://www.globenewswire.com/news-release/2026/11/06/3397876/0/en/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html?ref=bullished.co) — globenewswire.com

### More on Arcutis Biotherapeutics

- [Arcutis Lifts 2026 Sales Outlook To $535 Million–$545 Million As Zoryve Revenue Climbs 45%](https://www.bullished.co/arcutis-lifts-2026-sales-outlook-to-535-million-545-million-as-zoryve-revenue-climbs-45-013690d1/)
- [Arcutis CFO Defers 2027 Guidance, Says Sales Will 'Inflect' As Simone Biles Campaign Lifts Spending 60%](https://www.bullished.co/arcutis-cfo-defers-2027-guidance-says-sales-will-inflect-as-simone-biles-campaign-lifts-54bb0f6c/)
- [Arcutis Doubles Its Stock-Sale Program To $200 Million As Selling Costs Jump 60%](https://www.bullished.co/arcutis-doubles-its-stock-sale-program-to-200-million-as-selling-costs-jump-60-295dc133/)

[All Arcutis Biotherapeutics (ARQT) coverage →](https://www.bullished.co/tag/arqt/)